BG60526B2 - Фармацевтичен препарат - Google Patents

Фармацевтичен препарат Download PDF

Info

Publication number
BG60526B2
BG60526B2 BG098501A BG9850194A BG60526B2 BG 60526 B2 BG60526 B2 BG 60526B2 BG 098501 A BG098501 A BG 098501A BG 9850194 A BG9850194 A BG 9850194A BG 60526 B2 BG60526 B2 BG 60526B2
Authority
BG
Bulgaria
Prior art keywords
weight
dopa
decarboxylase inhibitor
hydrocolloid
preparation
Prior art date
Application number
BG098501A
Other languages
Bulgarian (bg)
English (en)
Inventor
Prabhakar Sheth
Jacques Tossounian
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of BG60526B2 publication Critical patent/BG60526B2/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BG098501A 1981-09-14 1994-02-21 Фармацевтичен препарат BG60526B2 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30149881A 1981-09-14 1981-09-14

Publications (1)

Publication Number Publication Date
BG60526B2 true BG60526B2 (bg) 1995-07-28

Family

ID=23163649

Family Applications (1)

Application Number Title Priority Date Filing Date
BG098501A BG60526B2 (bg) 1981-09-14 1994-02-21 Фармацевтичен препарат

Country Status (11)

Country Link
JP (1) JPS5857315A (enExample)
AT (1) AT385199B (enExample)
BE (1) BE894376A (enExample)
BG (1) BG60526B2 (enExample)
CH (1) CH652025A5 (enExample)
DE (1) DE3232873A1 (enExample)
FR (1) FR2512676B1 (enExample)
GB (1) GB2105590B (enExample)
IT (1) IT1158048B (enExample)
MX (1) MX9203173A (enExample)
NL (1) NL190746C (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6143108A (ja) * 1984-08-03 1986-03-01 Nippon Shinyaku Co Ltd 医薬品製剤及びその製造法
GB8507779D0 (en) * 1985-03-26 1985-05-01 Fujisawa Pharmaceutical Co Drug carrier
EP0198769A3 (en) * 1985-04-12 1987-09-02 Forest Laboratories, Inc. Floating sustained release therapeutic compositions
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
DE3642668A1 (de) * 1986-12-13 1988-06-23 Kamprad Joachim Schmerzmittel fuer menschen
EP0324947B2 (de) * 1987-12-31 1997-08-20 ASTA Medica Aktiengesellschaft Synergistische Kombination von Decarboxylasehemmern und L-Dopa-Pellets
EP0497977B1 (en) * 1989-10-26 1995-03-15 Nippon Shinyaku Company, Limited Gastric preparation
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5227167A (en) * 1991-06-11 1993-07-13 Alza Corporation Long-term delivery device including hydrophobic loading dose
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
AU8000494A (en) * 1993-10-29 1995-05-22 Reckitt & Colman Products Limited Gelatin capsule fill able to foam
AU692483B2 (en) * 1993-10-29 1998-06-11 R.P. Scherer Corporation Gelatin capsule fill able to foam
US5888540A (en) * 1993-10-29 1999-03-30 Sugden; Keith Pharmaceutical products
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
CA2501345A1 (en) * 2002-10-11 2004-04-22 Depomed Development, Ltd. Gastro-retentive levodopa delivery form
DE102004039196B4 (de) 2004-08-12 2008-07-31 Dr.Kamprad Kg Neue Formulierung für L-Tryptophan
USD627230S1 (en) 2008-05-22 2010-11-16 Colgate-Palmolive Company Container
DE102010023828A1 (de) * 2010-06-15 2011-12-15 IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH Pharmazeutisches Präparat, welches Entacapon, Levodopa und Carbidopa enthält
USD673861S1 (en) * 2012-03-28 2013-01-08 S.C. Johnson & Son, Inc. Dispensing system
DE102014003744A1 (de) 2014-03-10 2015-09-10 Laboratorium für Lebensmittelwissenschaft (FPE) - Eidgenössische Technische Hochschule Zürich (ETH) Produkt zur oralen Verabreichung bei Menschen oder Tieren mit mikrostrukturierten, gekapselten Inhaltsstoffen sowie Vorrichtung zum Herstellen eines derartigen Produkts und Verfahren zum Herstellen dieses Produkts
DE102022103658A1 (de) 2022-02-16 2023-08-17 Joachim Kamprad Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH409996A (de) * 1961-06-16 1966-03-31 Hoffmann La Roche Verfahren zur Herstellung von substituierten Hydrazinen
US3557292A (en) * 1968-08-16 1971-01-19 Hoffmann La Roche Compositions and methods for treating parkinson's disease with combinations of l-3,4-dihydroxyphenylalanine and a hydrazine
US3632778A (en) * 1970-06-10 1972-01-04 Hoffmann La Roche Tablets containing l-dopa
ZA713877B (en) * 1970-07-24 1972-03-29 Hoffmann La Roche Pharmaceutical composition
DE2305209A1 (de) * 1972-02-14 1973-08-23 Hoffmann La Roche Pharmazeutisches praeparat
CA1018456A (en) * 1972-06-26 1977-10-04 Hans Lowey Prolonged release lozenges
CH630257A5 (en) * 1975-03-17 1982-06-15 Hoffmann La Roche Sustained release formulation
US4126672A (en) * 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations

Also Published As

Publication number Publication date
MX9203173A (es) 1992-07-01
AT385199B (de) 1988-02-25
NL190746C (nl) 1994-08-01
DE3232873A1 (de) 1983-03-31
JPS5857315A (ja) 1983-04-05
GB2105590A (en) 1983-03-30
NL190746B (nl) 1994-03-01
FR2512676A1 (fr) 1983-03-18
BE894376A (fr) 1983-03-14
IT8223147A1 (it) 1984-03-07
CH652025A5 (de) 1985-10-31
GB2105590B (en) 1985-05-30
JPH0341447B2 (enExample) 1991-06-24
NL8203343A (nl) 1983-04-05
FR2512676B1 (fr) 1987-01-23
IT1158048B (it) 1987-02-18
ATA341582A (de) 1987-08-15
IT8223147A0 (it) 1982-09-07

Similar Documents

Publication Publication Date Title
US4424235A (en) Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
AU628754B2 (en) Therapeutic agents
US5292518A (en) Prolonged-release drug tablet formulations
US5840756A (en) Pharmaceutical composition of L-DOPA ester
JP5888549B2 (ja) 医薬組成物
AU668386B2 (en) Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU764742B2 (en) Dispersible compositions containing L-DOPA ethyl ester
MC1101A1 (fr) Composition a activite retardee
GB2105590A (en) Flotable controlled release preparations
BE1015217A5 (enExample)
EA021321B1 (ru) Новые композиции 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
EP0156592A2 (en) Substained release pharmaceutical capsules
EP3013327B1 (en) Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin
EP4272734A1 (en) Oral solid formulation for colon cleansing
KR100741937B1 (ko) 제제의 안정화 방법
WO2016084099A1 (en) Soft gelatin capsule composition of anti-tussive agents
WO2002102415A1 (en) Gastric floating system
BE839604A (fr) Composition a activite retardee
EA003584B1 (ru) Способ стимуляции отказа от курения или его снижения или предупреждения возобновления курения и применение пароксетина или его фармацевтически приемлемых солей или сольватов для получения лекарственного средства
JPH0645539B2 (ja) 鎮痛剤
WO2026099431A1 (en) Formulation comprising triethylenetetramine tetrahydrochloride
HK1094152A1 (zh) 抗血栓形成的化合物的可在口中分散的药物组合物
HK1094152B (en) Orodispersible pharmaceutical composition of an antithrombotic compound